This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ana.26380

This article is protected by copyright. All rights reserved.
Joseph L. DeRisi**, PhD, Chan Zuckerberg Biohub, Department of Biochemistry and Biophysics, University of California, San Francisco, CA

*Authors contributed equally to this work

** Authors contributed equally to this work; Co-Corresponding authors

**Corresponding Author Information**

Name: Joseph L. DeRisi
Address: 1700 4th street, QB3 room 404, San Francisco, CA 94110
Email: joe@derisilab.ucsf.edu
Phone: 415-418-4794

Name: Mark P. Gorman
Address: 300 Longwood Ave, Boston, MA, 02115
Email: mark.gorman@childrens.harvard.edu
Phone: 857-218-4794

**Number of words in the abstract (max 250):** 250

**Number of words in the introduction (max 500):** 379

**Number of words in the discussion (max 1500):** 870

**Number of words in the body of the manuscript, not including abstract, references, figure legends (max 4500):** 3830

**Number of figures and tables (max 8):** 7
Summary for social media if published

1. **Twitter handle of authors:** @cmandelbrehm

2. **What is current knowledge on the topic? (one to two sentences)** Clinical evidence suggests an autoimmune etiology in ROHHAD however molecular data supporting this hypothesis is lacking.

3. **What question did this study address? (one to two sentences)** Is pediatric ROHHAD a novel autoimmune paraneoplastic neurological disorder?

4. **What does this study add to our knowledge? (one to two sentences)** We identified autoantibodies to ZSCAN1 as the first potential biomarker for tumor-associated ROHHAD, thus supporting an autoimmune paraneoplastic syndrome in this poorly understood, devastating disease.

5. **How might this potentially impact on the practice of neurology? (one to two sentences)** Our findings provide in-roads to an improved route to diagnostics for ROHHAD and call for increased consideration of autoimmune paraneoplastic etiology in idiopathic pediatric syndromes.
Abstract

Objective: Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD), is a severe pediatric disorder of uncertain etiology resulting in hypothalamic dysfunction and frequent sudden death. Frequent co-occurrence of neuroblastic tumors have fueled suspicion of an autoimmune paraneoplastic neurological syndrome (PNS); however, specific anti-neural autoantibodies, a hallmark of PNS, have not been identified. Our objective is to determine if an autoimmune paraneoplastic etiology underlies ROHHAD.

Methods: Immunoglobulin G (IgG) from pediatric ROHHAD patients (n=9), non-inflammatory individuals (n=100) and relevant pediatric controls (n = 25) was screened using a programmable phage display of the human peptidome (PhIP-Seq). Putative ROHHAD-specific autoantibodies were orthogonally validated using radioactive ligand binding and cell-based assays. Expression of autoantibody targets in ROHHAD tumor and healthy brain tissue was assessed with immunohistochemistry and mass spectrometry, respectively.

Results: Autoantibodies to ZSCAN1 were detected in ROHHAD patients by PhIP-Seq and orthogonally validated in 7/9 ROHHAD patients and 0/125 controls using
radioactive ligand binding and cell-based assays. Expression of ZSCAN1 in ROHHAD tumor and healthy human brain tissue was confirmed.

**Interpretation:** Our results support the notion that tumor-associated ROHHAD syndrome is a pediatric PNS, potentially initiated by an immune response to peripheral neuroblastic tumor. ZSCAN1 autoantibodies may aid in earlier, accurate diagnosis of ROHHAD syndrome, thus providing a means toward early detection and treatment. This work warrants follow-up studies to test sensitivity and specificity of a novel diagnostic test. Lastly, given the absence of the ZSCAN1 gene in rodents, our study highlights the value of human-based approaches for detecting novel PNS subtypes.
Introduction

Rapid-onset Obesity with Hypothalamic Dysfunction, Hypoventilation and Autonomic Dysregulation (ROHHAD) is a poorly understood pediatric syndrome with high morbidity and mortality, distinguished by its unique progression of multi-system derangements\(^1,2\). Variable degrees of hypothalamic and presumed brainstem dysfunction manifest after age two as obesity, autonomic dysregulation and alveolar hypoventilation with risk of sudden death from respiratory or autonomic dysfunction\(^1-6\). Neuropsychiatric changes and seizures have been described\(^7,8\). Detailed longitudinal follow up describing ROHHAD’s natural history is limited\(^9\). Although incurable, early supportive care including respiratory support for hypoventilation may reduce morbidity\(^10,11\). Diagnosis remains difficult given lack of biomarkers and overlap with other pediatric disorders including congenital central hypoventilation syndrome (CCHS), Prader-Willi syndrome and other forms of genetic and non-genetic obesity\(^12-15\). Although recognized as a distinct disorder since 2000, ROHHAD is rare with fewer than 200 reported cases\(^1,5\). The etiology is unclear.

Thus far, most etiologic investigations into ROHHAD have focused on genetic susceptibility, without consistent results\(^16-19\). The presence of neuroblastic tumor (NT, including neuroblastoma, ganglioneuroblastoma, ganglioneuroma) defines a large subset of patients with ROHHAD (30-100% depending on the series), sometimes referred to as ROHHAD-NET\(^5,20\). NTs are similarly associated with CCHS, a genetic
condition due to mutations in PHOX2B, and opsoclonus-myoclonus syndrome (OMS), an autoimmune paraneoplastic neurological syndrome (PNS)\textsuperscript{21-23}. With respect to ROHHAD, several observations suggest an immune-mediated disease, including the presence of oligoclonal bands in cerebrospinal fluid (CSF) and immune-cell infiltrates in brain, including hypothalamus and brainstem at autopsy\textsuperscript{24-29}. In addition, some patients with ROHHAD have variable improvement with immunosuppressive therapy\textsuperscript{30,31}. Establishing ROHHAD as a PNS would have important implications for developing diagnostic biomarkers, highlighting the need for tumor identification and resection, and advancing the use of immunosuppressive treatments\textsuperscript{32}.

On a molecular level, a PNS can be defined by its association with autoantibodies to specific onconeural antigens, or proteins expressed in both the pathogenic tumor and healthy nervous system\textsuperscript{33}. Despite a suspicion of PNS in ROHHAD, evidence of anti-neural reactivity is limited and an associated onconeural antigen has not been identified\textsuperscript{29,34}. Here, we deployed human-specific phage-display immunoprecipitation and next-generation sequencing (PhIP-Seq) and complementary techniques to investigate a possible paraneoplastic etiology in ROHHAD. We find that IgG autoantibodies to protein Zinc finger and SCAN domain-containing protein 1 (ZSCAN1) are robustly associated with ROHHAD and may be useful as a diagnostic biomarker and advancing knowledge of this poorly understood disease.

**Methods**

All relevant ethical regulations were followed regarding animal experiments and human research participant involvement. For animal experiments, protocols were approved by
the Institutional Animal Care and Use Committee. For human samples we have obtained informed consent from all participants and/or their parents.

Patient recruitment. All local IRB regulations were followed at Boston Children’s Hospital (BCH) (protocol #09-02-0043) and University of California, San Francisco (protocol #13-12236). All patient specific data was extracted by chart review (LB, LK, ST) and samples obtained following family consent. ROHHAD subjects were identified by pediatric neuro-immunologists (L.B. or S.T.) on the basis of clinical suspicion for ROHHAD syndrome, without alternative diagnosis. Eight of 9 patients (ROHHAD-7 excluded) met criteria used to definite ROHAD syndrome\(^2\). Three patients were initially screened in a pilot study, 5 more Boston Children’s and 1 Washington University patients’ samples were subsequently obtained and added. Between 2010 and 2022 at BCH, one author (L.B.) evaluated 21 patients for possible ROHHAD syndrome, of whom 9 had a definite diagnosis, 8 of which were known to have tumors. Of these 9 patients, 8 had available samples for inclusion in the current study.

Autoantibody discovery and validation. For autoantibody discovery, we utilized the PhIP-Seq library and experimental protocol as previously described\(^3\). PhIP-Seq datasets were analyzed with a formalized analysis pipeline (generated in-house) that includes alignment of DNA reads to input library, conversion to peptide reads, summing of peptides by protein ID, normalization to 100,000 reads (RP100K) and calculating mean RP100K for each protein. Alignment of sequencing reads to the input library on a peptide-level was performed with RAPsearch2\(^3\) and command line
A Z-score enrichment for each protein was calculated based on mean RP100K generated from a large set of healthy controls. Z-score formula = \((\text{proteinX mean RP100K}_{\text{Experimental}} - \text{proteinX mean RP100K}_{\text{control}}) / (\text{Standard Deviation of proteinX in controls})\).

**293T cell-based assay (CBA): Immunocytochemistry and imaging.** 293T CBA transfections, immunocytochemistry and imaging were performed as previously described\(^3\). Cells were stained according to standard procedure with one of the following primary antibodies: Patient IgG (CSF 1:100, Serum 1:1000), commercial anti-ZSCAN1 IgG (1 ug/ml) or commercial anti-FLAG IgG (1 ug/ml), followed by staining with an appropriate secondary antibody (anti-Human IgG Alexa 488, anti-rabbit IgG or anti-mouse IgG Alexa 568). Images were captured using a Nikon Ti CSU-W1 Spinning Disk/High Speed Widefield microscope at the UCSF Nikon Core Facility with a Plan Apo 20x/0.75 or Plan Apo VC 100x/1.4 oil immersion lens. Image capture settings, including exposure time, laser intensity, aperture, and magnification, were kept constant for all conditions in the experiment and analyzed in ImageJ.

**293T cell-based assay: Slot-blot Western Blotting.** Twenty-four hours post-transfection, cells were washed once in cold 1XPBS, then harvested and lysed with RIPA buffer for 30 minutes at 4°C with gentle agitation. Lysates were spun down for 30 minutes at 16,000 x g at 4°C. Supernatants were diluted to a 1 mg/ml protein concentration using the BCA (Pierce) kit and prepared for SDS/PAGE and slot-blot western blotting. 4x
laemmli buffer was added to lysates, boiled for 5 minutes at 95°C, loaded onto a 4-12% gradient SDS-PAGE gel (Bio-Rad), then transferred to a 0.20 micron PVDF membrane. Membranes were blocked at room temperature for two hours in blocking buffer (LI-COR), then loaded onto a multiscreen apparatus to screen for multiple CSF or serum samples as well as commercial antibodies. Human CSF samples were loaded at 1:200, human serum samples were loaded at 1:10000, while commercial antibodies were loaded at 1:2000 and incubated overnight at 4°C. To visualize proteins of interest, anti-Human IgG (LI-COR 680) and anti-rabbit IgG (LI-COR 800) were loaded into wells and incubated for 2 hours at room temperature and scanned on Odyssey imaging system (LI-COR).

**Onconeural antigen investigation.** To examine candidate autoantigen expression in ROHHAD tumor and healthy human brain we used immunohistochemistry and immunoprecipitation-mass spectrometry (IP-MS), respectively. For tumor examination, fresh frozen tumor was embedded, sectioned, fixed on slides, stained and imaged according to standard procedures. To detect ZSCAN1 we immunostained with commercial antibody to ZSCAN1 (Rabbit, Thermo Fisher Scientific, PA552488) and anti-rabbit secondary. For IP-MS experiments, ~100 milligrams of frozen human hypothalamus was homogenized and prepared for IP and subsequent MS analysis. For IP, lysate was diluted to 0.5 mg/mL and one of the following antibodies was added at 1μg/mL: Rabbit anti-ZSCAN1 (Thermo Fisher Scientific, PA552488), Rabbit anti-ZSCAN1 (Sigma Aldrich HPA007938), Rabbit IgG control (Thermo Fisher Scientific,
Positive identification of ZSCAN1 required detection with two commercial antibodies and absence from isotype control. Two technical replicates were performed.

**Mass spectrometry analysis.** The protein bound magnetic beads were resuspended in 100 µL of 0.1% RapiGest SF Surfactant (Waters, Milford, MA) in 100mM ammonia bicarbonate. The proteins were reduced (5 mM dithiothreitol, 37 °C, 60 min) and alkylated (14 mM iodoacetamide, room temperature in dark, 45 min). 5 µg of trypsin was added to each sample for digestion overnight at 37 °C. Peptide-containing supernatant was separated from the magnetic beads and trifluoroacetic acid was added to the supernatant to adjust the pH to below 2. The sample was incubated at 37 °C for 30 minutes followed by centrifugation at 16,000 rcf for 10 minutes, and subject to desalting with RP-S cartridges on an AssayMAP Bravo platform (Agilent, Santa Clara, California) and resuspended in 0.1% formic acid.

Desalted peptides were analyzed on a Fusion Lumos mass spectrometer (Thermo Fisher Scientific, San Jose, CA) equipped with a Thermo EASY-nLC 1200 LC system (Thermo Fisher Scientific, San Jose, CA). Peptides were separated by capillary reverse phase chromatography on a 25 cm column (75 µm inner diameter, packed with 1.6 µm C18 resin, AUR2-25075C18A, Ionopticks, Victoria Australia). Peptides were introduced into the Fusion Lumos mass spectrometer using a gradient with 3–27 % buffer B (0.1% (v/v) formic acid in acetonitrile) for 105 min followed by 27-40 % buffer B for 15 min at a flow rate of 300 nL/min. Data was acquired in top speed data dependent mode with a duty cycle time of 1 s. Selected precursor ions from MS1 were subjected to fragmentation using higher-energy collisional dissociation (HCD) with quadrupole...
isolation window of 0.7 m/z, and normalized collision energy of 31%. HCD fragments were analyzed in the Ion Trap. Fragmented ions were dynamically excluded for a period of 45 seconds.

The resulting data were searched using SEQUEST HT on the Proteome Discoverer (2.2.0.388) platform, against a database combining Human proteins (downloaded January 28, 2021) and common contaminants. The precursor mass range was set to 350-5000 Da, the mass error tolerance was set to 10 ppm, and the fragment mass error tolerance to 0.6 Da. Enzyme specificity was set to trypsin, carbamidomethylation of cysteines (+57.021) was set as fixed modifications, oxidation of methionines (15.995) and acetylation of protein N-terminus (+42.011) was considered as variable modifications. Percolator was used to filter peptides and proteins to a false discovery rate of 1%. Abundance quantification was based on precursor ion intensities.

Animal Protocol. All animal protocols were in accordance with the regulations of the National Institute of Health and approved by the University of California San Francisco Institutional Animal Care and Use Committee (IACUC). Wildtype C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Adult mice (> postnatal day 42) were used for immunohistological screening of human patient antibodies.

Radioligand Binding Assay (RLBA). The RLBA was performed as described previously\(^4\). Briefly, full-length human ZSCAN1 was in vitro transcribed and translated with [\(^{35}\)S]-methionine in a T7 dependent system using a ZSCAN1 plasmid containing a
T7 promoter (Origene Cat: RC221074). The radiolabeled ZSCAN1 protein was then column purified and immunoprecipitated with 2.5ul serum or CSF per well using Sephadex protein A/G beads (Sigma Aldrich, St. Louis, MO; #GE17-5280-02 and #GE17-0618-05) in 96-well filtration plates (Corning, Corning, NY; #EK-680860). The plates were read out as counts per minute (cpm) using the Microbeta Trilux liquid scintillation plate reader (Perkin Elmer).

*Data availability.* Original data contributing to the main findings in our study as well as additional supplementary figures and tables are provided on Dryad repository (temporary link for review: https://datadryad.org/stash/share/P0zU0SM4Oth44F35oirk6pJhBFjlcGghDSByaCc2jWM). The dryad repository includes raw data for PhIP-Seq analysis, RLBA analysis, Mass Spectrometry, immunohistochemistry images and western blots. There are no data restrictions for this study.

**Results**

*Clinical profile of ROHHAD cohort.* The ROHHAD cohort consisted of 9 patients (ROHHAD-1 through 9) selected on the basis of clinical suspicion for ROHHAD syndrome, without alternative diagnosis (Table 1). Each patient was found to exhibit defining features of ROHHAD syndrome including rapid-onset of obesity between 2-5 years of age and multiple additional features of hypothalamic dysfunction. Three patients were described previously\(^1,7,37\). Hypoventilation was present in 8/9 at diagnosis. Eight of 9 patients were found to have NT (ROHHAD-1 through 8), while a single patient in this cohort was not known to have a tumor (ROHHAD-9), although work-up was
limited to chest x-ray and chest MRI without abdominal imaging. Eight of 9 subjects had clinical genetic testing without genetic syndromes identified to explain their phenotypes, including 8/9 with dedicated or whole exome testing ruling out PHOX2B mutations. Features suggestive of a neuroinflammatory process include comorbid autoimmune diseases (2/9), elevated CSF neopterin (3/9) and CSF-specific oligoclonal bands (1/8 tested). Improvement in symptoms was observed in 6/7 patients treated acutely with supportive care, tumor resection and immunosuppressive therapy at diagnosis. Response to immunosuppressive therapy was most clearly demonstrated in ROHHAD-6 in whom CO2 retention improved and worsened in parallel with changing steroid doses. Similarly, neurobehavioral symptoms improved for ROHHAD-77. Additional clinical details pertaining to autoimmune features and neurologic phenotypes for the ROHHAD cohort are provided in supplemental Table 1 and supplemental Table 2, respectively.

Clinical profile of control cohorts. Control cohort 1 (CC1) and control cohort 2 (CC2) were assembled for PhIP-seq screening and validation experiments, respectively. Clinical details and demographics pertaining to controls is provided in Supplemental Table 3 (CC1) and Supplemental Table 4 (Pediatric controls OMS and Obesity +NT).

Screening for autoantibodies using rodent based approaches. Immunohistochemical screening of patient antibodies against neural tissue, typically rodent, is a classical approach for identifying cryptic autoimmune etiologies among idiopathic neurological syndromes\textsuperscript{38-41}. In two independent laboratories (JDR, SJP), antibodies in CSF from
ROHHAD-1 through 6 were tested for immunoreactivity against mouse brain tissue. Neither identified anti-neural reactivity in any patient. Additional, independent assessment of autoantibodies to extracellular neural targets were also tested in 4 patients in this cohort using pre-established protocols for fixed and live rat neurons\textsuperscript{41,42} (see Supplemental Table 1). All studies were negative (negative data pertaining to immunohistochemistry using rodent based approaches available on Dryad).

Screening for autoantibodies using human-specific Phage-Display Immunoprecipitation and Sequencing (PhIP-Seq). The PhIP-seq library employed here displays a representation of the human proteome and has been used previously for detecting diagnostic PNS autoantibodies\textsuperscript{35,43}. As part of a discovery pilot, we screened CSF from 3 ROHHAD patients (ROHHAD 1-3) and plasma from CC1 (n=100). CC1 represents plasma from 100 de-identified blood donors courtesy of New York Blood Center. Individual PhIP-seq experiments were sequenced with the total number of DNA reads normalized to 100,000 reads, referred to as RP100K, to enable comparison of protein enrichments. An RP100K for each protein in the library was generated for each patient, then averaged according to cohort. To aid in candidate identification, ROHHAD-specific Z-score enrichments for each protein were generated, using CC1 values (see methods). All proteins with a ROHHAD mean RP100K $>$ 0 were plotted relative to Z-score enrichments (Fig 1). Candidate antigens were expected to satisfy the following criteria in at least 2 patients: a minimum level of recovery (RP100K$>$50) and minimum Z-score enrichment ($>$3). Of the $\sim$20,000 protein possibilities, only 1 protein, ZSCAN1, satisfied these criteria. Using the same criteria above, enrichment of ZSCAN1 was not observed
in other previously published autoimmune cohorts screened on the same PhIP-Seq platform including PNS syndromes anti-Yo (n = 36), anti-Hu (n = 44), anti-Ma2 (n = 2), anti-KLHL11 (n = 7) or patients with systemic Autoimmune Polyglandular Syndrome Type I (n = 39)\textsuperscript{35,43,44}.

**Orthogonal validation assays.** To further investigate the association of ZSCAN1 and ROHHAD syndrome, we repeated PhIP-seq with an expanded ROHHAD cohort (including the 3 original patients) and new set of controls (CC2). CC2 represents 27 de-identified healthy volunteers (plasma n = 3; sera n = 17, CSF n = 7) and 26 clinically relevant pediatric controls. Pediatric controls include: childhood obesity + NT (n = 1), and children with OMS (with NT n = 10, without NT n = 15). For all samples, ZSCAN1 RP100K is reported, as well as, Z-score enrichment based on our background control dataset CC1 (ZSCAN1 mean = 8.18 RP100K, standard deviation = 32.53 RP100K), with Z-score > 3 considered positive. We reproduced the association between ZSCAN1 and ROHHAD, showing enrichment in 7 of 9 ROHHAD patients (ROHHAD-1 to 7) and 0 of 50 samples from CC2 (Fig 2A). We next leveraged peptide-level data and found antigenicity within ZSCAN1 was largely restricted to the C-terminal of ZSCAN1, with patients displaying enrichment of overlapping peptides, increasing confidence in our findings (Fig 3). Intriguingly, patients ROHHAD-1 through 7 shared an antibody which bound to a common 11 amino acid (AA) epitope.

To confirm ZSCAN1 enrichment in our ROHHAD cohort, we tested for IP of recombinant ZSCAN1 in two orthogonal assays, including a radioligand binding assay
(RLBA) and 293T cell-based overexpression assay (CBA). For the 6 patients with paired CSF and sera (ROHHAD 1-6), ZSCAN1 enrichment in one sample type was sufficient to be called positive in a given assay. First, the RLBA with in vitro transcribed and translated full length ZSCAN1 protein revealed positive IP (fold change > 10) by ROHHAD patients 1 through 7 (sera n = 7/7; paired CSF n = 6/6) and no enrichment in CC2 healthy controls (Fig 2B). Low-level enrichment of ZSCAN1 was observed in 2 patients negative by PhIP-seq; ROHHAD-9 and OMS-4. Second, using immunocytochemistry and 293T cells expressing full-length ZSCAN1, we show colocalization of human antibodies with commercial antibody to ZSCAN1 for ROHHAD patients 1 through 7 (sera n=2 ROHHAD-1 and 3; CSF n = 6 ROHHAD-1 through 6). Co-localization is not observed for ROHHAD-8, ROHHAD-9 or controls, including OMS-4 (Fig 2C). Taken together, ROHHAD-1 through 7 reproduced ZSCAN1 enrichment in two antibody-based orthogonal assays, thus limiting possibility of false-positives and validating autoantibodies to ZSCAN1 in this cohort45.

Of note for 293T CBAs, we observed increased sensitivity to ZSCAN1 autoantibody detection using CSF compared to sera. This is exemplified best in data collected from the 6 patients with paired CSF and sera (ROHHAD-1 through 6). In 293T CBAs, ZSCAN1 autoantibodies were detected using 6/6 CSF samples (Fig 4A). In contrast, only 2/6 paired sera were positive (Fig 4B). To rule out technical artifacts, sera samples were re-tested on CBA at several dilutions 1:100, 1:1000, 1:2000 and 1:5000, with no change in seronegativity. We further tested for recognition of ZSCAN1 autoantibodies using whole cell lysates prepared from 293T cells overexpressing ZSCAN1. When
western blotting denatured lysates with CSF we reproduce positive signal with 6/6 CSF (Fig 5).

*Testing antigen expression in tumor and brain.* Typically, autoantibodies associated with PNS target antigens that are expressed in relevant tumor and healthy brain, otherwise known as onconeural antigens. To test for tumor expression of ZSCAN1, one NT from ROHHAD-3 was sectioned and immunostained with a previously validated commercial antibody to ZSCAN1 (Fig 4). A rabbit secondary only control was used to test for nonspecific staining of Rabbit IgG to infiltrating human IgG and Fc proteins in the tumor. ZSCAN1 expression was apparent in the ROHHAD-associated tumor (Fig 6). To test for hypothalamic expression of ZSCAN1, mass spectrometry analysis was performed using immunoprecipitation from human hypothalamic lysates using commercial antibodies to ZSCAN1. ZSCAN1 peptides were readily detectable, consistent with protein expression in this tissue (data available on Dryad repository).

**Discussion**

In this work, we describe a proteome-wide screen for autoantibodies in patients with ROHHAD, a complex, diagnostically challenging syndrome with severe and often life-threatening symptoms. By comparing antibody profiles from ROHHAD patients to a large set of clinically relevant controls, we found autoantibodies to ZSCAN1 are a putative biomarker of ROHHAD, and thus have potential utility in identifying ROHHAD earlier in the disease course.
All patients in this ROHHAD cohort (n= 9/9) exhibited the defining symptoms of the syndrome including rapid-onset obesity and hypothalamic dysfunction, with an onset between two to five years of age\(^1,2\). NTs were present in 8/9 patients. Autoantibodies to ZSCAN1 were identified in 7 of 9 patients tested (sera n=7/9, paired CSF n=5/6) by PhIP-Seq, all of whom had NTs. Each of the 7 PhIP-Seq positive samples (ROHHAD-1 through 7) were validated by at least two orthogonal assays, including 293T CBA and RLBA. Two assay validation limits the possibility of false-positive results and is increasingly accepted as a prerequisite for defining bona fide autoantigens\(^{38,47}\).

Two ROHHAD patients (ROHHAD-8 and 9) were negative for ZSCAN1 autoantibodies, although CSF was not available for testing. Interestingly, ROHHAD-8 was in clinical remission when their sera was collected and at an older age (24 yrs.) compared to other patients (age range = 2 – 10 years, median 3 years), who all exhibited active symptoms at sample collection. ROHHAD-9 did not have a tumor identified but exhibited the ROHHAD phenotype and active disease. Future experiments to determine the association of ZSCAN1 antibodies and ROHHAD syndrome in the absence of NT are warranted.

Previous clinical reports suggested ROHHAD could be a PNS by virtue of its co-occurrence with a tumor type already associated with a different PNS (OMS), clinical features of autoimmunity and the failure to identify consistent genetic associations\(^{3,7,8,16-19,24,26-31}\). Our findings collectively support the notion of a PNS etiology. First, autoantibodies to the molecular antigen (ZSCAN1) were found in the majority (7/9) of ROHHAD cases, and in all from cases with a NT identified. The robust association of ZSCAN1 autoantibodies (>70% of patients) with NT associated ROHHAD fulfills the
new diagnostic criteria for PNS etiology\textsuperscript{47}. Second, ZSCAN1 expression in human hypothalamus is consistent with the target tissues affected in ROHHAD patients. Third, ZSCAN1 was found to be expressed in NT tissue from a patient with ROHHAD. Fourth, the presumed intracellular localization of ZSCAN1 (www.uniprot.org, www.proteinatlas.org), together with our expression in ROHHAD NTs as well as healthy nervous system tissue, is reminiscent of other classical PNS onconeural antigens.

Antibodies to intracellular onconeural antigens are a biomarker for a major subtype of PNS, such as cerebellar degeneration-related protein 2-like in anti-Yo PNS and neuronal ELAV-like proteins 2,3,4 in anti-Hu PNS\textsuperscript{33}. In these cases, autoantibodies themselves are not thought to be directly pathogenic, and the diseases are often less consistently responsive to tumor resection and immunosuppressive therapy compared to PNS with antibodies to extracellular antigens. Consistent with the hypothesis of PNS, ROHHAD patients have variable responses (duration and magnitude) to immunosuppressive therapy or tumor resection and may respond better to earlier, more aggressive regimens\textsuperscript{3,7,30,31}.

The ZSCAN1 protein is a putative zinc finger transcription factor (znTF) that contains a single SCAN domain and 3 Cysteine2-Histidine2 (C2H2) zinc finger domains (uniprot.org). Despite nearly equal representation of SCAN domain (84 AA) and C2H2 domains (100 AA), antigenicity in ZSCAN1 is biased to the C2H2 domains, a functional region for DNA and RNA binding\textsuperscript{49} (Fig. 3). Further, although ~700 human proteins containing C2H2 domains with the motif C-X2-4-C-X12-H-X2-6-H (where X is any AA) are present in our PhIP-seq library, no other ZnTF’s were significantly enriched in more than one patient (Z-score > 1), highlighting the specificity of the motif identified by PhIP-
Importantly, the ZSCAN1 gene lacks a genetic ortholog in rodents, including mice and rats, with evolutionary divergence towards primate-specificity in the C2H2 region\textsuperscript{49-51}. These observations suggest the putative epitope within ZSCAN1 has a high likelihood of being exclusive to primate. To our knowledge, a primate-specific epitope in autoimmune disease has not yet been described.

A common autoantibody among ROHHAD patients suggests a route to a molecular diagnostic. Here we demonstrate the value of the human-specific PhIP-seq approach for ROHHAD biomarker discovery. ZSCAN1 has no genetic ortholog in rodents, so the classical rodent based approach for PNS autoantibody detection failed. Our results suggest CBAs or RLBAs on CSF may be sufficient to detect ZSCAN1 autoantibodies in a clinical lab setting and could be offered as a stand-alone test or added to existing paraneoplastic antibody panels. In the case of ROHHAD, these results also suggest that CSF may be the most sensitive sample type for testing, since ZSCAN1 was not always detectable in sera, particularly on CBA, as is true for many PNS.

To summarize, we provide a robust finding of autoantibodies to ZSCAN1 as a marker for tumor-associated pediatric ROHHAD. ZSCAN1 expression in tumor and human hypothalamus provides further evidence to support the clinical suspicion that ROHHAD is a novel type of PNS. This is the first identified intracellular antigen in a PNS unique to children. Further experiments are required to test the utility of ZSCAN1 autoantibodies for diagnosis in ROHHAD patients with and without tumors and NTs without paraneoplastic syndromes, define the clinical spectrum of PNS ROHHAD and to understand how immune targeting of ZSCAN1 contributes to the dramatic clinical
complications seen in patients with ROHHAD syndrome.

Acknowledgements

This research was supported by ROHHAD Fight, Inc, the Shore Foundation, the OMS Life Foundation, the Repository Core for Neurological Disorders, Department of Neurology, Boston Children’s Hospital, and the IDDRC (NIH P30HD018655) and NIH R01MH122471. We would also like to acknowledge the New York Blood Center for contribution of healthy control plasma. Instituto Carlos III (ISCIII, P20/00197 [JD]), and “La Caixa” Foundation (JD). CMA is supported by NIDDK (K23DK120899). Acknowledge the UCSF Nikon Core Facility for microscope imaging equipment and guidance. JDL is funded by a grant from Chan Zuckerberg Biohub. JDL, MRW, SJP and CMB are funded by the National Institute of Mental Health (NIMH) of the NIH (award 1R01MH122471-01). SJP, BT are also funded by the Brain Research Foundation (Scientific Innovations Award). CMB is also funded by The Emiko Terasaki Foundation (Project 7027742 / Fund B73335) and by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (award 1K99NS117800-01). SEV is funded by the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH (award 1F30DK123915-01).

Author contributions:

CMB, LB and BT contributed equally to this work including drafting of the manuscript. LB, MPG, JDR, MRW and SJP contributed to the conception and design of the study. CMB, SAM, HR AFK, BT, SEV, PLM, LZ, FM, JEE, WWS, JD, HAS, KCZ, LMK, UK,
CMA, ST, LMK, MRW contributed to the acquisition and analysis of data; LB, LMK, CM, BT contributed to drafting the text and/or preparing the figures.

**Conflicts of Interest**

Nothing to report.

**Figure Legends**

**Figure 1.** PhIP-Seq screen implicates ZSCAN1 as a candidate autoantigen in ROHHAD. CSF from 3 ROHHAD patients (ROHHAD-1 to 3) and plasma from a large set of “healthy controls” (n = 100) were tested by PhIP-Seq. Individual data was averaged according to cohort. All proteins with a ROHHAD mean RP100K >0 are plotted against ROHHAD Z-score enrichments compared to healthy controls. Non-ZSCAN1 proteins are denoted with blue dots, ZSCAN1 is denoted with a red dot.

**Figure 2.** Validation of autoantibodies to ZSCAN1 in ROHHAD patients. In panel a and b, enrichment of ZSCAN1 by PhIP-Seq and Radio Ligand Binding Assay (RLBA) was compared between ROHHAD patients (n=9), non-inflammatory healthy controls (n=24) and pediatric controls including children with OMS with and without NT (n=25) and an obesity patient with NT (n=1). Data represents the average of two independent technical replicates. a, PhIP-Seq analysis. Each column represents an individual sample. A heatmap of total ZSCAN1 RP100K is shown in the top row. To enable comparisons between the majority of samples with lower signal we added a ceiling value of 1000 RP100K. Z-score enrichments based on our 100 human donor dataset are plotted below, with samples that have Z-score enrichments > 3 colored with blue
squares. Grey squares indicate Z-score < 3.  

b, RLBA testing immunoprecipitation of recombinant ZSCAN1 by ROHHAD patients and controls. For all samples, fold change was calculated by dividing by the mean value from control sera (n=17, mean = 20.83).  
c, Representative image showing immunostaining of 293T cells expressing full-length ZSCAN1 with human CSF and commercial antibody to ZSCAN1 (Rabbit). Top row shows immunostaining with control CSF. Bottom row shows staining with ROHHAD-3 CSF. Colocalization is indicated by yellow in the merge images (far right both rows).

**Figure 3. Peptide-level ZSCAN1 enrichments by ROHHAD patients, informed by PhIP-seq.** Cartoon graphic of the 408 amino acid ZSCAN1 protein with annotated SCAN and C2H2 domains is depicted below. Horizontal tracks above ZSCAN1 represent peptide enrichment data from individual ROHHAD patients or aggregated data from control cohorts. All peptides belonging to ZSCAN1 with enrichment RP100K >50 were plotted as red bars, merging together peptides with overlapping regions within individual tracks to reflect span of antigenic area. The black bar above all tracks represents an 11 AA region of overlap in 100% (7/7) patients within the C-terminal domain. The amino acid sequence for the region of overlap is depicted above the black bar.

**Figure 4. Validation of ZSCAN1 autoantibodies in CSF and sera of ROHHAD patients using 293T Cell-Based Assays.** (A) CSF: Immunocytochemistry with 293T cells expressing full-length ZSCAN1 and immunostaining with CSF (1:10) from ROHHAD patients and commercial antibody to ZSCAN1 (Rabbit, 1:1000 Invitrogen). Anti-human IgG-488 was used to visualize human IgG and anti-Rabbit IgG-567 was
used to visualize anti-ZSCAN1 commercial antibody. Exposure times and post-image processing and thresholding was kept constant across conditions within the experiment. Co-localization was assessed qualitatively through observance of yellow in merged images. (B) Sera: Immunocytochemistry with 293T cells expressing full-length ZSCAN1 and immunostaining with Sera (1:100) from ROHHD patients and commercial antibody to ZSCAN1 (Rabbit, 1:100 Invitrogen). Anti-human IgG-488 was used to visualize human IgG and anti-Rabbit IgG-567 was used to visualize anti-ZSCAN1 commercial antibody. Exposure times and post-image processing and thresholding was kept constant across conditions within the experiment. Co-localization was assessed qualitatively through observance of yellow in merged images. Note colocalization in ROHHD Sera-1 and 3.

Figure 5. Detection of ZSCAN1 autoantibodies with slot-blot western blotting using ROHHD CSF. Whole cell-lysates from HEK293T cells expressing transfected with full-length human ZSCAN1 cDNA were separated on a 1-well 4-12% Tris-HCl protein gel, transferred to a PVDF membrane and immunoblotted in a slot-blot device (BioRad). Primary and secondary antibodies were added to lanes as indicated. Primary antibodies were loaded in lanes 1-12. Lanes 13 and 15 served as secondary-only controls. Primary antibodies are as follows: Lanes 1 through 7: ROHHD 1-7 CSF (1:200); Lane 8 through 12: Controls 1-5 CSF (1:200), Lane 13: Blank, Lane 14: Commercial antibody to ZSCAN1 (Sigma, Rabbit, 1:2000); Lane 15: Blank, Lane 16: Commercial antibody to Flag (CST, Rabbit, 1:2000). Secondary antibodies to visualize human IgG Lanes 1-12: Goat anti-human IgG (LICOR680). Secondary antibodies to
visualize commercial antibodies to ZSCAN1 and FLAG Lanes 14 and 16: goat anti-Rabbit IgG (LICOR800).

**Figure 6. Immunohistochemical detection of ZSCAN1 in NT associated with ROHHAD patient-3.** Fixed neuroblastoma tissue was immunostained with either (top) Anti-Rabbit-488 secondary alone or (bottom) primary antibody to ZSCAN1 (Rabbit) and Anti-Rabbit-488 Secondary. Green: Anti-Rabbit-488 secondary, Blue: DAPI to identify nuclei.
References


A

<table>
<thead>
<tr>
<th>SERA</th>
<th>CONTROLS</th>
<th>ROHHAD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Total ZSCAN1
ZSCORE >3

0  Reads  >1000

B

<table>
<thead>
<tr>
<th>SERA</th>
<th>CONTROLS</th>
<th>ROHHAD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

HEK 293T + pCMV6-ZSCAN1-myc-flag + Control CSF (NIC-019) + anti-ZSCAN1 Ab

Anti-Human IgG

Anti-Rabbit IgG (ZSCAN1)

Merge (+ DAPI)

HEK 293T + pCMV6-ZSCAN1-myc-flag + Patient CSF (ROHHAD-003) + anti-ZSCAN1 Ab

Anti-Human IgG

Anti-Rabbit IgG (ZSCAN1)

Merge (+ DAPI)
INPUT (all lanes): 293T whole cell lysate expressing full length human ZSCAN1-FLAG

<table>
<thead>
<tr>
<th></th>
<th>ROHHAD 1</th>
<th>ROHHAD 2</th>
<th>ROHHAD 3</th>
<th>ROHHAD 4</th>
<th>ROHHAD 5</th>
<th>ROHHAD 6</th>
<th>CONTROL 1</th>
<th>CONTROL 2</th>
<th>CONTROL 3</th>
<th>CONTROL 4</th>
<th>CONTROL 5</th>
<th>CONTROL 6</th>
<th>BLANK</th>
<th>BLANK</th>
<th>Anti-ZSCAN1</th>
<th>BLANK</th>
<th>BLANK</th>
<th>Anti-FLAG</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
<td>16</td>
<td>17</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Accepted Article
ROHHAD-003 Neuroblastic Tumor

Secondary only control (No primary Ab + Anti-Rabbit-488 secondary + DAPI)

Anti-ZSCAN1 primary Ab (Rabbit) + Anti-Rabbit-488 secondary + DAPI
<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age (yr) at Onset</th>
<th>ROHHAD Features</th>
<th>ROHHAD suspected</th>
<th>Age at Onset (z-score)</th>
<th>Respiratory phenotype</th>
<th>Endocrinopathies</th>
<th>Autonomic Dysfunction</th>
<th>Tumor Type (age at identification)</th>
<th>CSF Results</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (2yrF)</td>
<td>9</td>
<td></td>
<td></td>
<td>10.1 (CSF), 10.6 (Serum)</td>
<td>2 yr (Z=+2.7 at 9y)</td>
<td>CSA, 24 hour HV</td>
<td>Yes</td>
<td>Yes</td>
<td>Ganglio-neuroma (9 yr)</td>
<td>1 WBC/m³, 8 RBC/m³, 0 OCBs</td>
</tr>
<tr>
<td>2 (5yrF)³⁵</td>
<td>6</td>
<td></td>
<td></td>
<td>6.0 (CSF), 6.0 (serum)</td>
<td>5 yr (Z=+2.9 at 6 yr)</td>
<td>Night-time HV</td>
<td>Yes</td>
<td>Yes</td>
<td>Ganglio-neuroma (6 yr)</td>
<td>0 WBC/m³, 54 RBC/m³, 0 unique CSF OCB</td>
</tr>
<tr>
<td>3 (2yrM)</td>
<td>3</td>
<td></td>
<td></td>
<td>0.2 (Serum) 4.0 (CSF)</td>
<td>2 yr (Z=+5,2a t 2y)</td>
<td>CSA, 24 hour HV</td>
<td>Yes</td>
<td>Yes</td>
<td>Neuroblastoma (3 yr)</td>
<td>5 WBC/m³, 525 RBC/m³, 13 OCBs at diagnosis (4 OCB after 10 months, 2 OCB Neopterin of 75 (el) after 2.5 years)</td>
</tr>
<tr>
<td>4 (2yrM)</td>
<td>2</td>
<td></td>
<td></td>
<td>2.7 (Serum) 2.7 (CSF), 2.6 (Tumor)</td>
<td>2 yr (Z=+2.1 at 2y)</td>
<td>CSA, 24 hour HV</td>
<td>Yes</td>
<td>Yes</td>
<td>Ganglio-neuroblastoma (2 yr)</td>
<td>4 WBC/m³, 2 RBC/m³, 2 OCBs (nl), neopterin 20 (nl)</td>
</tr>
<tr>
<td>5 (3yrM)</td>
<td>3</td>
<td></td>
<td></td>
<td>3.8 (Serum) 3.8 (CSF), 3.8 (Tumor)</td>
<td>3 yr Z=+5.2 at 3y)</td>
<td>CSA, 24 hour HV</td>
<td>Yes</td>
<td>Yes</td>
<td>Ganglio-neuroblastoma (3yr)</td>
<td>0 WBC/m³, 0 RBC/m³, 0 OCBs, Neopterin 41 (nl) (repeat after 5.5 months similar)</td>
</tr>
<tr>
<td>6 (3yrM)</td>
<td>5</td>
<td></td>
<td></td>
<td>5.2 (CSF), 5.2 (Serum)</td>
<td>3 yr(Z=+3.9 at 5y)</td>
<td>24 hour HV</td>
<td>Yes</td>
<td>Yes</td>
<td>Ganglio-neuroblastoma , intermixed (5yr)</td>
<td>36 WBC/m³, 0 RBC/m³, 0 OCBs, Neopterin 94 (el)</td>
</tr>
<tr>
<td>7 (2yrF)⁷</td>
<td>4</td>
<td></td>
<td></td>
<td>11 (Serum)</td>
<td>2 yr OSA</td>
<td>Yes</td>
<td>No</td>
<td>Ganglio-neuroblastoma (3 yr)</td>
<td>Not tested</td>
<td>Alive 11yr</td>
</tr>
<tr>
<td>8 (3yrF)⁷</td>
<td>8</td>
<td></td>
<td></td>
<td>24.1 (Serum) 25.2 (CSF)</td>
<td>3 yr</td>
<td>24 hour HV</td>
<td>Yes</td>
<td>No</td>
<td>Ganglio-neuroblastoma (7 yr)</td>
<td>2 WBC/m³, 60 RBC/m³, 141 protein, 0 OCBs, Neopterin 21 (nl)</td>
</tr>
<tr>
<td>9 (3yrM)</td>
<td>12</td>
<td></td>
<td></td>
<td>7.5 (Serum)</td>
<td>3 yr (Z=+4.7 at 4y)</td>
<td>CSA, 24 hour HV</td>
<td>Yes</td>
<td>No</td>
<td>None (abdomen not imaged)</td>
<td>2 WBC/m³, 31 RBC/m³, 0 unique CSF OCB, Neopterin 76 (el)</td>
</tr>
</tbody>
</table>

CSF = Cerebrospinal Fluid, CSA= central sleep apnea, el = elevated, HV = hypoventilation, nl = normal, OCB = Oligoclonal Band, OSA = Obstructive Sleep Apnea, Yr = years. * All tested CSF had normal protein, glucose and IgG index values except where noted. #Endocrine and other symptomatic treatment not recorded. Further details on ROHHAD phenotypes in supplemental tables.